News & Events

PRINT PDF

C-Path Appoints Tufts’ Jonathan M. Davis as Senior Advisor in Pediatrics

TUCSON, Ariz., September 16, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jonathan M. Davis, M.D., as Senior Advisor in Pediatrics working with its International Neonatal Consortium (INC) and advising on drug and device development in infants and children, effective immediately.

Davis is Vice-Chair of Pediatrics and Chief of Newborn Medicine at Tufts Children’s Hospital and Professor of Pediatrics at Tufts University School of Medicine. His research has focused on neonatal drug development, including optimizing approaches to treat neonatal abstinence syndrome.

“On behalf of everyone at C-Path and our INC partnership, we celebrate the appointment of Dr. Davis to the leadership team working in pediatrics,” said Klaus Romero, M.D., F.C.P., C-Path Chief Science Officer. “Jon has the experience, expertise and dedication to help advance C-Path’s goal as a global collaborator to forge an optimized regulatory path for evaluating the efficacy and safety of therapies not just for neonates, but the broader pediatric population as well.”

Davis has a long history of working with C-Path on various projects, including being INC’s co-director since its inception six years ago and as a co-principal investigator of its FDA-funded Real-World Data, Real-World Evidence project. “Jon is an outstanding colleague and true supporter of the C-Path model,” said Kanwaljit Singh, M.D., MPH, C-Path’s Director of Pediatric Programs. “We are very grateful for the opportunity to have Jon work with us on future pediatric initiatives at C-Path.”

Davis is currently funded by National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) to develop better biomarkers and outcome measures for clinical trials and new and existing therapeutics to improve neonatal outcomes. He serves as Chair of the Neonatal Advisory Committee in the Office of the Commissioner at FDA and Associate Director of the Tufts Clinical and Translational Science Institute. He is also the Co-PI of a recent $8 million NIH award to Tufts Medical Center to fund a national clinical trial to study the integration of targeted genomic sequencing into neonatal diagnosis and care.

Davis is currently funded by National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) to develop better biomarkers and outcome measures for clinical trials and new and existing therapeutics to improve neonatal outcomes. He serves as Chair of the Neonatal Advisory Committee in the Office of the Commissioner at FDA and Associate Director of the Tufts Clinical and Translational Science Institute. He is also the Co-PI of a recent $8 million NIH award to Tufts Medical Center to fund a national clinical trial to study the integration of targeted genomic sequencing into neonatal diagnosis and care.

“I am honored by this appointment and see it as an outstanding opportunity to grow and strengthen pre-competitive sciences, ultimately benefiting pediatric populations,” said Davis. “As an innovator in research and development of treatments for preterm infants, I’m excited to work with C-Path in this expanded partnership with the goal of accelerating medical product development in pediatrics.”

INC will hold its annual scientific meeting October 19 – 20, 2021. Those interested in attending may register for free here.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 56.5% funded by FDA/HHS, totaling $16,749,891, and 43.5% funded by non-government source(s), totaling $12,895,366. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit FDA.gov.


About C-Path

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

Media Contact:

Kissy Black
C-Path
615.310.1894
kblack@c-path.org